SCORTEN score in Stevens-Johnson syndrome and TEN (also searched with possessive/alternate eponym spelling where applicable, ICD-10: L51.3) is a rigorously validated, severity-of-illness prognostic scoring system specifically designed to estimate inpatient mortality in patients suffering from Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) 1,3. SJS and TEN represent a life-threatening spectrum of delayed-type hypersensitivity cutaneous adverse reactions—predominantly triggered by xenobiotics such as aromatic anticonvulsants, allopurinol, and sulfonamide anti-infectives—characterized by extensive necrosis and detachment of the epidermis and mucous membranes 1,2. Because clinical deterioration can occur rapidly within hours of presentation, accurate risk stratification is paramount to guide triage into specialized burn units or intensive care units (ICUs) 3,4. The SCORTEN model utilizes seven independent, easily obtainable clinical and laboratory parameters assessed within the first 24 hours of hospital admission to reliably predict patient survival outcomes 3, allowing clinicians to objectively gauge disease severity and tailor aggressive supportive or immunomodulatory protocols 5,6.

Etiology & Risk Factors

  • Pharmacological Triggers (High-Risk Xenobiotics): Over 80% of SJS and TEN cases are directly attributable to drug exposure, with latency periods ranging from 4 to 28 days following initial administration 1,2. High-risk classes include aromatic antiepileptics (carbamazepine, phenytoin, phenobarbital, lamotrigine), sulfonamide antibiotics, allopurinol, non-steroidal anti-inflammatory drugs (oxicam derivatives), and various anti-infectives (fluoroquinolones) 1,2,4.
  • Genetic Predisposition & Pharmacogenetics: Strong associations exist between specific human leukocyte antigen (HLA) allotypes and drug hypersensitivity. HLA-B*15:02 strongly predicts carbamazepine-induced SJS/TEN in Han Chinese and Southeast Asian populations, while HLA-B*58:01 confers high risk for allopurinol hypersensitivity, prompting mandatory genetic screening guidelines prior to drug initiation in high-risk groups 4.
  • Infectious Triggers: Although less common than drug-induced etiologies, atypical pathogens such as Mycoplasma pneumoniae and viral infections (herpes simplex virus, cytomegalovirus) can precipitate SJS, particularly in pediatric cohorts where skin detachment is typically minimal and mucosal involvement predominates 1.
  • Host Vulnerability Factors: Underlying immunocompromised states, active malignancies, human immunodeficiency virus (HIV) infection, and advanced age significantly increase susceptibility to severe drug reactions and elevate baseline SCORTEN components 3,4.

Pathophysiology

Stevens-Johnson syndrome and toxic epidermal necrolysis represent a T-cell mediated delayed-type hypersensitivity (Type IVc) reaction characterized by extensive keratinocyte apoptosis across the skin and mucosal epithelia 1,3. Following systemic exposure, drug metabolites or altered peptides bind to native human leukocyte antigens and are presented to naive CD8+ cytotoxic T-lymphocytes, driving clonal expansion and recruitment of specialized effector memory cells into cutaneous microvasculature 1,4. Upon activation, these cytotoxic lymphocytes—alongside natural killer (NK) cells—release massive quantities of cytotoxic cytolytic proteins, most notably granulysin, perforin, granzyme B, and soluble Fas ligand (sFasL) 4. The interaction between Fas ligand on immune cells and Fas receptors on epidermal keratinocytes triggers a caspase-dependent intracellular apoptotic cascade 1,4. Simultaneously, granulysin acts directly on lipid membranes to induce widespread keratinocyte cell death independently of classical receptor pathways 4. This explosive, confluent apoptotic death leads to full-thickness epidermal necrosis and cleavage at the dermo-epidermal junction 1,3. Grossly, this manifests as widespread blistering and sheet-like sloughing of the skin, leaving raw, weeping dermis vulnerable to severe fluid loss, electrolyte imbalances, thermoregulatory failure, and invasive secondary sepsis 3,4.

SCORTEN score in Stevens-Johnson syndrome and TEN — Pathophysiological Cascade & Clinical Flowchart 1 Drug Haptenation & Immune Trigger Systemic exposure to culprit medications (e.g., antiepileptics, sulfonamides) triggers delayed-type hypersensitivity reaction. 2 Keratinocyte Apoptosis Cascade Cytotoxic T-lymphocytes and natural killer cells release granulysin, perforin, and granzyme B, driving massive keratinocyte death. 3 Dermo-Epidermal Separation Extensive cleavage occurs at the dermo-epidermal junction, resulting in widespread epidermal detachment and blistering. 4 Clinical Manifestation & Scoring Widespread denudation, positive Nikolsky sign, mucosal erosion, and physiological derangements captured by the SCORTEN parameters. 5 Critical Care Intervention Burn unit isolation, fluid/electrolyte management, infection surveillance, and supportive care to reduce multiorgan failure and mortality.

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: The clinical course typically initiates with a painful 1-to-3-day prodromal phase featuring high-grade fever, malaise, arthralgias, stinging conjunctivae, and severe dysphagia before any cutaneous lesions become apparent 1,3. Patients frequently report an intense burning sensation in the skin and mucous membranes that disproportionately exceeds the visible cutaneous findings initially 1.
  • Physical Examination & Named Clinical Signs: Cutaneous eruptions progress rapidly from tender, dusky-red purpuric macules with atypical targetoid centers to flaccid blisters that rupture easily 1,3. A positive Nikolsky sign—shearing off of the superficial epidermis upon gentle lateral thumb pressure on erythematous skin—is universally present in involved zones 3. Mucosal involvement affects at least two mucosal sites (ocular, oral, nasal, anogenital) in over 90% of cases, presenting with painful hemorrhagic erosions, pseudomembrane formation, and severe conjunctivitis that threatens permanent visual impairment 1,3.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationUrgent full-thickness skin punch biopsy demonstrating full-thickness epidermal necrosis, basal layer vacuolization, and sparse perivascular lymphocytic infiltration with minimal dermal inflammation 1,3.
Laboratory PanelComplete blood count often reveals profound leukopenia, neutropenia, and lymphopenia; comprehensive metabolic panel frequently shows acute kidney injury, hyponatremia, hypoalbuminemia, and elevated inflammatory markers (CRP) 3.
Imaging / Radiology (X-ray, US, CT, MRI)Chest radiography (CXR) and targeted imaging performed to rule out pulmonary involvement (e.g., tracheobronchial sloughing, pneumonitis) and screen for occult infection sources during systemic deterioration 3,6.
ECG / Histopathology / Procedural12-lead ECG and continuous telemetry to monitor for electrolyte-induced dysrhythmias during active fluid resuscitation; direct inspection of mucosal surfaces via laryngoscopy or bronchoscopy if airway sloughing is suspected 3,4.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Disease Classification (BSA)SJS involves < 10% Body Surface Area (BSA) detachment; SJS/TEN overlap involves 10–30% BSA; TEN involves > 30% BSA detachment 1,3.
SCORTEN Variable: Age1 point assigned if patient age is strictly greater than 40 years at presentation 3.
SCORTEN Variable: Malignancy1 point assigned if there is an active underlying hematologic or solid organ malignancy 3.
SCORTEN Variable: Tachycardia1 point assigned if initial heart rate exceeds 120 beats per minute 3.
SCORTEN Variable: Detachment1 point assigned if initial epidermal detachment exceeds 10% of total body surface area on Day 1 3.
SCORTEN Variable: BUN1 point assigned if serum urea (blood urea nitrogen) is greater than 10 mmol/L (> 28 mg/dL) 3.
SCORTEN Variable: Glucose1 point assigned if initial serum glucose is greater than 14 mmol/L (> 252 mg/dL) 3.
SCORTEN Variable: Bicarbonate1 point assigned if serum bicarbonate is less than 20 mmol/L (reflecting metabolic acidosis) 3.
SCORTEN Score InterpretationScore 0–1: ~3% mortality; Score 2: ~12% mortality; Score 3: ~35% mortality; Score 4: ~58% mortality; Score >= 5: >90% mortality, mandating immediate ICU/burn unit admission 3.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Staphylococcal Scalded Skin Syndrome (SSSS)Primarily affects infants and young children; cleavage occurs intraepidermally at the granular layer via exfoliative toxins A and B; mucous membranes are characteristically spared; negative Nikolsky sign on unaffected areas 4.
Erythema Multiforme MajorCharacterized by typical or raised atypical target lesions with limited distribution (often acral); minimal mucosal involvement (< 10% BSA); lacks extensive sheet-like epidermal sloughing and severe systemic toxicity 1,3.
Generalized Bullous Fixed Drug EruptionWell-demarcated dusky bullous plaques that recur in the exact same anatomical locations upon re-exposure to the culprit drug; systemic symptoms are milder and rapid mucosal denudation is less pervasive than in TEN 2,4.
Acute Generalized Exanthematous Pustulosis (AGEP)Presents with acute, widespread non-follicular sterile pustules on an erythematous base accompanied by leukocytosis and fever; skin detachment is minimal or absent; resolves rapidly with desquamation within 15 days upon drug cessation 4.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Immediate transfer of the patient to an Intensive Care Unit or specialized Burn Center is mandatory for barrier nursing, strict aseptic handling, and thermoregulation (maintaining ambient room temperature at 30–32°C to prevent hypothermia) 3,4. Prompt, complete withdrawal of all suspected offending medications is the single most critical therapeutic intervention determining survival 1,3,4.
  • First-Line Medical / Pharmacological Therapy: Aggressive supportive care forms the undisputed backbone of management 4,5. Fluid resuscitation protocols resemble burn management formulas (e.g., modified Parkland formula adjusted for transepidermal water loss, targeting urine output of 0.5–1.0 mL/kg/h), utilizing crystalloids while avoiding excessive fluid overload 3,4. Nutritional support via early enteral tube feeding is initiated to meet hypermetabolic demands and promote mucosal healing 3. Systemic immunomodulatory therapies (such as systemic corticosteroids, intravenous immunoglobulin [IVIG] at 2 g/kg total dose divided over 2–4 days, cyclosporine at 3–5 mg/kg/day, or targeted biologics) remain a subject of active clinical trial investigation, with current consensus prioritizing expert-guided combination or monotherapy tailored to early presentation windows 3,4,5.
  • Surgical / Interventional Indications: Conservative wound management is standard; aggressive mechanical debridement of detached epidermis is avoided to allow necrotic layers to act as a natural biological dressing over the underlying healing dermis, supplemented by non-adherent silicone or lipidocolloid dressings 3,4. Emergency ophthalmology consultation is required immediately upon admission for daily lysis of symblephara, copious saline irrigation, and application of prophylactic antibiotic or corticosteroid eye drops and amniotic membrane transplantation for severe ocular involvement 3.

Complications & Prognosis

  • Acute Complications: Fluid loss, electrolyte derangements, hypovolemic shock, hypermetabolic catabolic states, and secondary sepsis driven by skin and pulmonary colonization (commonly by Staphylococcus aureus and Pseudomonas aeruginosa) represent the leading causes of acute mortality 3,4. Tracheobronchial sloughing can lead to acute respiratory distress syndrome (ARDS) and airway obstruction 3.
  • Long-Term Sequelae: Chronic ocular complications occur in up to 50% of survivors, including dry eye syndrome, trichiasis, symblepharon formation, corneal scarring, and permanent visual loss 1,3. Cutaneous sequelae include pigmentary dyschromia, scarring, eruptive nail dystrophy, and urethral strictures or vaginal stenosis from mucosal synechiae 3.
  • Prognosis & Mortality Rates: Overall mortality ranges from 10% to 30% for toxic epidermal necrolysis, but is heavily stratified by the baseline SCORTEN score calculated within the first 24 hours of admission, making it an indispensable prognostic instrument in clinical practice 3,6.